EnWave’s Terpene Max™ REV™ Drying Process Surpasses Industry Averages for Room Dried Cannabis
DECEMBER 08, 2020 | 6:00 AM
EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the “Company”), announces today the successful research and development results of a new terpene retention process for drying cannabis using Radiant Energy Vacuum (“REV™”) dehydration technology. Third-party, lab-verified results demonstrate that EnWave’s patented REV™ technology can deliver a higher percentage of retained terpenes, approximately 10% higher, than traditional cannabis drying methods such as air drying or rack/room drying. The Company offers scalable, continuous REV™ machinery that can process up to 28 metric tons of high-terpene, dried cannabis per year using the Terpene Max™ process, and up to 46 metric tons of dried cannabis to be used for extraction purposes per year.
This new process, branded as Terpene Max™, further demonstrates the advantages of the Company’s scalable, proprietary vacuum-microwave drying technology for the global cannabis industry. Terpene Max™ ensures that drying temperatures remain well below 40 degrees Celsius for the entire drying process, which takes less than two hours.
Chart: The data in the chart above was analyzed at an independent testing facility. The results shown represent the average percentage of terpenes retained from three separately analyzed samples of the same batch of dried cannabis.
The initial quantitative results from using the new Terpene Max™ drying program on a specific low-THC cannabis strain demonstrated an average terpene retention level of 88 percent when compared to the fresh flower, making it materially superior to traditional air or rack/room drying where terpene retention averages 79 percent.
The tests were conducted for the Company by accredited, third-party testing facilities using cannabis product dried with large-scale, continuous REV™ technology at a licensed partner’s facilities against standard room-dried protocols. Further data, analysis and certified results will be released in a white paper that will be published in January 2021.
Terpenes are known to have therapeutic effects and are foundational to aromatherapies. Industry research shows that terpenes from cannabis work synergistically with cannabinoids to deliver a better user experience.
EnWave believes that the Terpene Max™ process has the potential to create an ultra-premium consumer product. The Company will be executing further trials with multiple cannabis strains in the coming months to understand the full potential of Terpene Max™ on ultra-premium combustible flowers.
Since obtaining Health Canada’s approval for its independent cannabis research and development lab, EnWave has used this opportunity to expand research and to develop programs such as Terpene Max™. With a fully commissioned R&D facility, the Company is now available to perform cannabis testing and demonstrations for prospective partners evaluating the use of REV™ technology to process cannabis.
With EnWave now able to conduct on-site trials with various cannabis strains, the perceived technology risk is reduced for prospective licensees.
REV™ drying technology provides cannabis producers with a rapid and gentle drying solution that produces premium cannabis products for both extraction and combustion while significantly reducing processing delays. The REV™ process can also reduce the bioburden in the product and lowers the risk of crop loss due to microbes and other quality issues. REV™ has been embraced by several licensed cannabis and hemp producers in Canada, Switzerland, New Zealand, Australia, and the United States of America.
EnWave Corporation, a Vancouver-based advanced technology company, has developed a Radiant Energy Vacuum (“REV™”) – an innovative, proprietary method for the precise dehydration of organic materials. EnWave has further developed patented methods for uniformly drying and decontaminating cannabis through the use of REV™ technology, shortening the time from harvest to marketable cannabis products.
REV™ technology’s commercial viability has been demonstrated and is growing rapidly across several market verticals in the food, and pharmaceutical sectors, including legal cannabis. EnWave’s strategy is to sign royalty-bearing commercial licenses with innovative, disruptive companies in multiple verticals for the use of REV™ technology. The company has signed over thirty royalty-bearing licenses to date. In addition to these licenses, EnWave established a Limited Liability Corporation, NutraDried Food Company, LLC, to manufacture, market and sell all-natural dairy snack products in the United States, including the Moon Cheese® brand.
EnWave has introduced REV™ as the new dehydration standard in the food and biological material sectors: faster and cheaper than freeze drying, with better end product quality than air drying or spray drying. EnWave currently has three commercial REV™ platforms:
1. nutraREV® which is used in the food industry to dry food products quickly and at low-cost, while maintaining high levels of nutrition, taste, texture and colour; and
2. quantaREV® which is used for continuous, high-volume low-temperature drying.
More information about EnWave is available at www.enwave.net.
Mr. Brent Charleton, CFA
President & CEO
For further information:
Brent Charleton, CFA
President & CEO at +1 (778) 378-9616
Dan Henriques, CA, CPA,
Chief Financial Officer at +1 (604) 835-5212
Safe Harbour for Forward-Looking Information Statements: This press release may contain forward-looking information based on management’s expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company’s strategy for growth, product development, market position, expected expenditures, and the expected synergies following the closing are forward-looking statements. All third party claims referred to in this release are not guaranteed to be accurate. All third party references to market information in this release are not guaranteed to be accurate as the Company did not conduct the original primary research. These statements are not a guarantee of future performance and involve a number of risks, uncertainties and assumptions. Although the Company has attempted to identify important factors that could cause actual results to differ materially, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.